NEW YORK — Veradermics Inc. shares skyrocketed more than 42% Monday, surging to $96.60 in morning trading after the dermatology-focused biopharmaceutical company announced strongly positive topline results from its Phase 2/3 clinical trial of VDPHL01, an oral treatment for male pattern hair loss that demonstrated early, consistent and robust hair growth.

The New Haven, Connecticut-based company, which went public earlier this year, saw its market capitalization jump by more than $1 billion in a single session as investors rushed to buy shares following the news. Trading volume was exceptionally heavy, with millions of shares changing hands in the first hours of the session.

Veradermics said its lead candidate VDPHL01 achieved statistically significant hair growth in the pivotal “302” study involving men with mild-to-moderate pattern hair loss. The oral, non-hormonal therapy showed rapid onset of action, with visible improvements noted as early as eight weeks and continuing through the 24-week endpoint. The results position VDPHL01 as a potential first-in-class treatment in a market long dominated by topical minoxidil and oral finasteride.

Breakthrough in Hair Loss Treatment

The company plans to hold a conference call Tuesday to discuss the detailed results. Analysts hailed the data as “transformational,” noting that VDPHL01 could capture a significant share of the multibillion-dollar global hair loss market if approved. Leerink Partners raised its price target on the stock to $90 from $75 following the announcement, maintaining an Outperform rating.

Veradermics CEO Dr. Reid Waldman expressed excitement in a prepared statement. “These results represent a major milestone not only for Veradermics but for the millions of men seeking safe, effective and convenient solutions for hair loss,” he said. The company is also advancing studies for female pattern hair loss, marking the first Phase 3 program of its kind in the U.S.

Company Background and IPO Success

Veradermics went public in February 2026 at $17 per share and has seen extraordinary volatility since its debut. The stock has more than quadrupled in value this year, driven by investor enthusiasm for its pipeline of dermatology and aesthetics products. The company focuses on turning common skin and hair concerns into proven therapeutic solutions through rigorous clinical development.

With cash reserves strengthened by its upsized IPO, Veradermics is well-funded to complete its ongoing Phase 3 programs and prepare for potential regulatory submissions. The company ended 2025 with significant cash on hand and has been aggressively advancing its clinical timeline.

Market Reaction and Analyst Views

Wall Street reacted enthusiastically to the news. Several firms reiterated Buy ratings, citing the strong efficacy data and large addressable market for hair loss treatments. Jim Cramer highlighted the stock on his show, calling it a “double or nothing” opportunity in the aesthetics space.

However, some analysts cautioned that the stock’s rapid run-up leaves it vulnerable to pullbacks. Valuation concerns persist, with the company still in the pre-revenue stage and facing competition from established players. Shares remain well below their recent 52-week high but have shown remarkable resilience.

Broader Industry Context

The positive results come at a time of growing interest in non-hormonal hair loss solutions. Current treatments like finasteride carry potential side effects that deter many patients, creating an opening for new therapies. Veradermics’ approach, if successful, could disrupt the market and offer a convenient oral option for both men and women.

The dermatology and aesthetics sector has seen increased investor attention in recent years, driven by aging populations and rising demand for cosmetic and therapeutic solutions. Veradermics’ progress validates the potential for innovation in this space.

What’s Next for Veradermics

The company will now focus on completing its remaining Phase 3 trials, including studies in female patients. Topline data from additional trials is expected later this year and in 2027. If approved, VDPHL01 could reach the market as early as 2028, representing a major commercial opportunity.

For investors, Monday’s surge underscores the high-risk, high-reward nature of clinical-stage biotech stocks. While the data appears compelling, full approval and commercial success are still years away and subject to regulatory hurdles.

As Veradermics continues its journey from clinical development to potential commercialization, the company’s progress will be closely watched by patients, physicians and investors alike. The strong Phase 2/3 results mark a pivotal moment that could transform treatment options for pattern hair loss and reward shareholders who bet on the company’s innovative approach.

Blackpool scheme will include 19 shipping containers

New jobs are now on offer as Blackpool’s ambitious Southbeach Streetfood project moves closer.

The new food destination is located opposite the Sandcastle Waterpark on South Shore promenade and will feature 19 converted shipping containers.

It will include food concessions ranging from Thai and Mexican to Spanish tapas and wood fired pizza.

The site will offer seating for up to 400 diners, and be designed with entertainment space so it can host events and music, with screens to show big sporting occasions.

It was hoped the attraction would be ready to open in June but the physical preparations needed for the groundwork have taken longer than anticipated and now it looks set to launch in July.

FBS Engineering of Poulton has officially begun transforming the shipping containers that will form the backbone of the development after recently moving into a larger workshop to accommodate the scale of the project.

Jamie Willacy, Director of Southbeach Streetfood UK Limited, said a lot of work had been going on behind the scenes.

He said: “Things are moving forward again. Engineers will start work on the foundations next week, ready for the groundworks to begin, in preparation for the mezzanine floor to be put in place.

“In the background, work has already started on the first six of the 19 containers, cutting out the doors and lining the insides with insulation.

“There has been a slight delay in the preparation to make sure everything is absolutely correct, so we’re looking at July rather than June now.

“We’ll definitely be up and running in time for the summer holidays.”

The project places a strong emphasis on sustainability and ethical trading with menus designed to reduce food waste and ingredients sourced from local suppliers wherever possible.

Alongside the food offering, visitors can expect live music from local artists, children’s activities, dance showcases, live cookery demonstrations and a curated bar featuring beers, wines and spirits.

Jamie said: ” We’re also excited to announce new job opportunities for Southbeach Streetfood

“If anyone would love to be part of a fresh new food and hospitality destination on the Prom, now is the perfect time to take a look.

“Whether you’re experienced in customer service, hospitality or just ready for your next opportunity, this could be your chance to join something exciting from the very start.”

Those interested can apply here: https://southbeachstreetfood.co.uk/job-opportunities/

To find all the planning applications, traffic diversions, road layout changes, alcohol licence applications and more in your community, visit the Public Notices Portal.